Roivant Sciences Ltd.

Stocks

ROIV

BMG762791017

Market Closed - Nasdaq 00:00:00 22/10/2026 +04			5-day change	1st Jan Change
36.80 ^USD	+5.38%		+9.46%	+69.59%

10-21	Roivant Sciences Ltd. - Special Call
10-21	AI Leaders Rally, Service Giants Retrench

Transcript : Roivant Sciences Ltd. - Special Call

Published on 10/21/2026 at 10:50 pm +04

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good day, and thank you for standing by. Welcome to the Roivant's CLARITY Phase III Study Results Conference Call. [Operator Instructions] Please note

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about Roivant Sciences Ltd.

10-21	Roivant Sciences Ltd. - Special Call
10-21	AI Leaders Rally, Service Giants Retrench
10-21	Roivant Sciences' Brepocitinib Achieves Primary Endpoint in Two Phase 3 Trials in Non-Infectious Uveitis	MT
09-23	US Equity Futures Slightly Lower Pre-Bell as Traders Await Developments in US-Iran Talks	MT
09-23	Roivant's Immunovant Unit to Stop IMVT-1402 Development in Cutaneous Lupus Erythematosus	MT
09-22	Roivant Sciences Ltd. Presents at Bank of America Global Healthcare Conference 2026, Sep-22-2026 12:20 PM
09-17	Stifel Nicolaus Initiates Roivant Sciences With Buy Rating, $51 Price Target	MT
09-10	Roivant Sciences Ltd. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-10-2026 10:00 AM
09-09	Roivant Sciences Ltd. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-09-2026 01:00 PM
09-08	Top Midday Gainers	MT
09-08	Roivant Sciences Ltd. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-08-2026 10:15 AM
09-08	Roivant Sciences Ltd. - Special Call
09-08	US Equity Futures Mostly Lower as Traders Assess Rising Oil, Canadian Retaliatory Tariffs	MT
09-08	Top Premarket Gainers	MT
09-08	Roivant Announces Positive Results From Phase 2 PHocus Clinical Trial And Unveils Ongoing Phase 3 PHrontier Study	CI